Lemtrada Is More Deadly Than Originally Thought

Lemtrada Stroke Lawsuit News

A recent analytical study shows that Lemtrada causes more deaths and from a greater variety of sources

Thursday, October 10, 2019 - Lemtrada is a monoclonal antibody manufactured by Sanofi Genzyme and is highly effective in blocking the CD52 protein and protecting the neuron sheathing from firing off unpredictably. The drug, however, is not without controversy as its side effects are among the worst in the industry. Multiple Sclerosis News Today has published a shocking report that claims that anti-multiple sclerosis drug Lemtrada (alemtuzumab) is more deadly than patients have been led to believe. Lemtrada is already classified as a drug of last resort and is to be given only to those in the most advanced stages of relapse remitting multiple sclerosis (RRMS). Patients in the later stages of RRMS are usually more than willing to try just about anything and some say that if they die from the treatment, so be it. MS News Today reports that deaths have occurred within one month of a patient getting a Lemtrada treatment. Until now, Lemtrada was being blamed on causing strokes in patients while they sat in the chair receiving the Lemtrada Intravenous (IV) drip treatment. Lemtrada.com defines the signs of a stroke as drooping of parts of the face, weakness on one side, sudden severe headache, difficulty with speech, and neck pain." Lemtrada lawsuits are represented by top national attorneys advising and representing consumers harmed by numerous dangerous drugs and medical devices and offer a free consultation.

In a study published by BiomedCentral.com titled: "Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis" investigators queried the European Medicines Agency database and found instances of "Sporadic fatal adverse events ... during treatment of multiple sclerosis with alemtuzumab." Ten cases of Lemtrada-induced death were identified, six within a month, "one from an intracerebral hemorrhage, two from acute multiple organ failure and septic shock, one from listeriosis, one from pneumonia and one from agranulocytosis."

Lemtrada patients also need to worry about infections caused by the treatment itself. Lemtrada naturally weakens a patient's blood counts and makes them more vulnerable to disease. Lemtrada patient that have experienced serious adverse medical consequences first reported swelling in the throat, irregular heartbeat and chest pain as well as chest tightness and trouble breathing. Lemtrada's toxicity destroys the smooth inner lining of the arteries (arterial dissection) leading to the heart and brain and can cause a blot clot to develop, potentially leading to heart attack and stroke.

Relapse remitting multiple sclerosis (RRMS) causes the body's nerve sheathing to wear thin and fire off without warning, making physical control impossible. WebMd.com tells us that RRMS usually begins when a person is in their 20s or 30s. RRMS patients have periodic attacks called relapses followed by recovery periods with few or no symptoms. Over time the disease progresses the symptoms of an attack become more severe and prolonged and the periods of remission decrease until a patient is left in a state of constant attack. Lemtrada patients need to be monitored by their doctor for signs of a stroke, heart attack, or other causes of sudden death for the first 24 hours during and after a Lemtrada drip treatment.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.